These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 3826998

  • 1. The precursors of fecapentaenes. A preliminary report.
    Van Tassell RL, Wilkins TD.
    Ann Ist Super Sanita; 1986; 22(3):933-41. PubMed ID: 3826998
    [No Abstract] [Full Text] [Related]

  • 2. Isolation and structure elucidation of fecapentaenes-12, potent mutagens from human feces.
    Hirai N, Kingston DG, Van Tassell RL, Wilkins TD.
    J Nat Prod; 1985; 48(4):622-30. PubMed ID: 4045474
    [No Abstract] [Full Text] [Related]

  • 3. General structure of "fecapentaenes"--the mutagenic substances in human faeces: a preliminary report.
    Bruce WR, Baptista J, Che T, Furrer R, Gingerich JS, Gupta I, Krepinsky JJ, Grey AA, Yates P.
    Naturwissenschaften; 1982 Nov; 69(11):557-8. PubMed ID: 7155190
    [No Abstract] [Full Text] [Related]

  • 4. On distribution of different fecapentaenes, the fecal mutagens, in the human population.
    Baptista J, Bruce WR, Gupta I, Krepinsky JJ, van Tassell RL, Wilkins TD.
    Cancer Lett; 1984 Apr; 22(3):299-303. PubMed ID: 6713371
    [Abstract] [Full Text] [Related]

  • 5. The fecapentaenes, potent mutagens from human feces.
    Kingston DG, Van Tassell RL, Wilkins TD.
    Chem Res Toxicol; 1990 Apr; 3(5):391-400. PubMed ID: 2133089
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Stabilization and quantitative analysis of fecapentaenes in human feces, using synthetic fecapentaene-12.
    Kleinjans JC, Pluijmen MH, Hageman GJ, Verhagen H.
    Cancer Lett; 1989 Jan; 44(1):33-7. PubMed ID: 2917340
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Absorption through the skin of sensitizing and nonsensitizing substances related to the active principle of poison ivy.
    Baer H, Godfrey H.
    Adv Biol Skin; 1971 Jan; 11():161-5. PubMed ID: 4124136
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Animal experiments on pharmacokinetics and biotransformation following administration of radioactive-labelled propiramfumarate].
    Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA.
    Arzneimittelforschung; 1974 Apr; 24(4):632-43. PubMed ID: 4406933
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.